Active surveillance and response evaluation strategy after neoadjuvant therapy for esophageal cancer
Liu Yunsong1, Men Yu1,2, Hui Zhouguang1,2
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract：A considerable proportion of esophageal carcinoma patients could achieve pathological complete response (pCR) after neoadjuvant therapy, for whom accurate response evaluation and active surveillance rather than surgery‐aiming to avoid the complications, mortality and reduced quality of life after surgery‐has become a research hotspot. To detect residual disease and predict pCR accurately by appropriate method(s) is the key of active surveillance strategy. In this article, we elaborated the active surveillance strategy of esophageal cancer and characteristics of different evaluation methods in terms of radiology, pathology and combined detection.
Liu Yunsong,Men Yu,Hui Zhouguang. Active surveillance and response evaluation strategy after neoadjuvant therapy for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 848-853.
[1] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074‐2084. DOI: 10.1056/NEJMoa1112088. [2] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open‐label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796‐2803. DOI: 10.1200/JCO.2018.79.1483. [3] Seely AJ, Ivanovic J, Threader J, et al. Systematic classification of morbidity and mortality after thoracic surgery[J]. Ann Thorac Surg, 2010, 90(3):936‐942; discussion 942. DOI: 10.1016/j.athoracsur.2010.05.014. [4] Schandl A, Lagergren J, Johar A, et al. Health‐related quality of life 10 years after oesophageal cancer surgery[J]. Eur J Cancer, 2016, 69:43‐50. DOI: 10.1016/j.ejca.2016.09.032. [5] van der Wille BJ, Noordman BJ, Neijenhuis L, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study[J]. Ann Surg, 2021, 274(6):1009‐1016. DOI: 10.1097/SLA.0000000000003636. [6] Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic us,FDG PET for assessment of response to neoadjuvant therapy‐‐systematic review[J]. Radiology, 2005, 236(3):841‐851. DOI: 10.1148/radiol.2363041042. [7] de Gouw D, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta‐analysis[J]. J Thorac Oncol, 2019, 14(7):1156‐1171. DOI: 10.1016/j.jtho.2019.04.004. [8] Konieczny A, Meyer P, Schnider A, et al. Accuracy of multidetector‐row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer[J]. Eur Radiol, 2013, 23(9):2492‐2502. DOI: 10.1007/s00330‐013‐2844‐8. [9] Eyck BM, Onstenk BD, Noordman BJ, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta‐analysis[J]. Ann Surg, 2020, 271(2):245‐256. DOI: 10.1097/SLA.0000000000003397. [10] van Rossum P, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta‐analysis[J]. Gastrointest Endosc, 2016, 83(5):866‐879. DOI: 10.1016/j.gie.2015.11.026. [11] Jost C, Binek J, Schuller JC, et al. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)[J]. Gastrointest Endosc, 2010, 71(7):1114‐1121. DOI: 10.1016/j.gie.2009.12.015. [12] van der Bogt RD, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer[J]. Endoscopy, 2019, 51(4):326‐332. DOI: 10.1055/a‐0795‐3220. [13] Eloubeidi MA, Cerfolio RJ, Bryant AS, et al. Efficacy of endoscopic ultrasound in patients with esophageal cancer predicted to have N0 disease[J]. Eur J Cardiothorac Surg, 2011, 40(3):636‐641. DOI: 10.1016/j.ejcts.2010.12.054. [14] Valkema MJ, Noordman BJ, Wijnhoven BPL, et al. Accuracy of 18F‐FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer[J]. J Nucl Med, 2019, 60(11): 1553‐1559. DOI: 10.2967/jnumed. 118.224196. [15] Fang P, Musall BC, Son JB, et al. Multimodal imaging of pathologic response to chemoradiation in esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 102(4):996‐1001. DOI: 10.1016/j.ijrobp.2018.02.029. [16] Li QW, Qiu B, Wang B, et al. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion‐weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study[J]. Dis Esophagus, 2018, 31(2)DOI: 10.1093/dote/dox121. [17] van Rossum PS, van Lier AL, van Vulpen M, et al. Diffusion‐weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J]. Radiother Oncol, 2015, 115(2):163‐170. DOI: 10.1016/j.radonc.2015.04.027. [18] Heethuis SE, van Rossum PS, Lips IM, et al. Dynamic contrast‐enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy[J]. Radiother Oncol, 2016, 120(1):128‐135. DOI: 10.1016/j.radonc.2016.05.009. [19] Heethuis SE, Goense L, van Rossum P, et al. Dw‐MRI and DCE‐MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer[J]. Acta Oncol, 2018, 57(9):1201‐1208. DOI: 10.1080/0284186X.2018.1473637. [20] Sarkaria IS, Rizk NP, Bains MS, et al. Post‐treatment endoscopic biopsy is a poor‐predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer[J]. Ann Surg, 2009, 249(5):764‐767. DOI: 10.1097/SLA.0b013e3181a38e9e. [21] Noordman BJ, Spaander M, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965‐974. DOI: 10.1016/S1470‐2045(18)30201‐8. [22] Chen PC, Chen YC, Lai LC, et al.Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5):1996‐2003. DOI: 10.1016/j.ijrobp.2011.02.036. [23] Hsu FM, Cheng JC, Chang YL, et al.Circulating mRNA profiling in esophageal squamous cell carcinoma identifies FAM84B as a biomarker in predicting pathological response to neoadjuvant chemoradiation[J]. Sci Rep, 2015, 5:10291. DOI: 10.1038/srep10291. [24] Wen J, Yang H, Liu MZ, et al. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo‐chemoradiotherapy[J]. Ann Oncol, 2014, 25(9):1769‐1774. DOI: 10.1093/annonc/mdu201. [25] Wen J, Luo K, Liu H, et al. MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy[J]. Ann Surg, 2016, 263(5):942‐948. DOI: 10.1097/SLA.0000000000001489. [26] Li SH, Rau KM, Lu HI, et al. Pre‐treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3‐4 oesophageal squamous cell carcinoma[J]. Eur J Cardiothorac Surg, 2012, 42(6):958‐964. DOI: 10.1093/ejcts/ezs136. [27] Djuric‐Stefanovic A, Micev M, Stojanovic‐Rundic S, et al. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade[J]. Eur J Radiol, 2015, 84(12):2477‐2484. DOI: 10.1016/j.ejrad.2015.09.025. [28] Heinzow HS, Seifert H, Tsepetonidis S, et al. Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy‐‐results of a multicenter cohort analysis[J]. J Gastrointest Surg, 2013, 17(6):1050‐1057. DOI: 10.1007/s11605‐013‐2189‐2. [29] Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy,endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer[J]. Ann Surg, 2008, 248(6):902‐908. DOI: 10.1097/SLA.0b013e31818f3afb. [30] Arnett A, Merrell KW, Macintosh EM, et al. Utility of 18F‐FDG PET for predicting histopathologic response in esophageal carcinoma following chemoradiation[J]. J Thorac Oncol, 2017, 12(1):121‐128. DOI: 10.1016/j.jtho.2016.08.136. [31] Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review[J]. Radiology, 2010, 254(3):707‐717. DOI: 10.1148/radiol.09091324. [32] Vollenbrock SE, Voncken F, Bartels LW, et al. Diffusion‐weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer: a systematic review[J]. Radiother Oncol, 2020, 142:17‐26. DOI: 10.1016/j.radonc.2019.07.006. [33] Cho N, Im SA, Cheon GJ, et al. Integrated 18F‐FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2018, 45(3):328‐339. DOI: 10.1007/s00259‐017‐3849‐3. [34] de Gouw D, Maas MC, Slagt C,et al. Controlled mechanical ventilation to detect regional lymph node metastases in esophageal cancer using uspio‐enhanced MRI; comparison of image quality[J]. Magn Reson Imaging,2020, 74:258‐265. DOI: 10.1016/j.mri.2020.09.020. [35] Yang Z, He B, Zhuang X, et al. CT‐based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy[J]. J Radiat Res, 2019, 60(4):538‐545. DOI: 10.1093/jrr/rrz027. [36] Hu Y, Xie C, Yang H, et al.Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma[J]. JAMA Netw Open, 2020, 3(9):e2015927. DOI: 10.1001/jamanetwork open.2020.15927. [37] Hu Y, Xie C, Yang H, et al. Computed tomography‐based deep‐learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma[J]. Radiother Oncol, 2021, 154:6‐13. DOI: 10.1016/j.radonc.2020.09.014. [38] van Rossum PSN, Fried DV, Zhang L, et al. The incremental value of subjective and quantitative assessment of 18F‐FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer[J]. J Nucl Med, 2016, 57(5): 691‐700. DOI: 10.2967/jnumed. 115.163766. [39] Beukinga RJ, Hulshoff JB, Mul V, et al. Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging 18F‐FDG PET imaging biomarkers in patients with esophageal cancer[J]. Radiology, 2018, 287(3):983‐992. DOI: 10.1148/radiol.2018172229. [40] Eng CW, Fuqua JL, Grewal R, et al. Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET‐CT useful?[J]. Clin Imaging, 2013, 37(3): 468‐474. DOI: 10.1016/j. clinimag. 2012.08.003. [41] Qian D, Pang Q. Definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery in patients who achieved clinical complete response when induction treatment finished for locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1): S86‐S87. DOI: 10.1016/j. ijrobp. 2019.06.556. [42] Maher SG, McDowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation[J]. Ann Surg, 2011, 254(5):809‐816; discussion 816‐817. DOI: 10.1097/SLA.0b013e31823699f2. [43] Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer[J]. Ann Oncol, 2012,23(10):2638‐2642. DOI:10.1093/annonc/mds210. [44] Blank S, Lordick F, Bader F, et al. Post‐therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation[J]. Gastric Cancer, 2015, 18(2):314‐325. DOI: 10.1007/s10120‐014‐0367‐x. [45] Borggreve AS, Mook S, Verheij M, et al.Preoperative image‐guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study[J]. BMC Cancer, 2018, 18(1):1006. DOI: 10.1186/s12885‐018‐4892‐6.
2022, Vol. 31 
